17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
05 Nov 08 Affymax Completes Enrollment In PEARL 2, 2nd Of 4 Phase 3 Clinical Trials Of Hematide To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Europe, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
22 Sep 08 Fresenius Medical Care Continues To Reopen Dialysis Clinics After Ike
A week after Hurricane Ike battered the Texas coast and left millions of people without electricity, Fresenius Medical Care North America has reopened nearly all of its dialysis facilities. In the Houston area, 29 of 32 Fresenius dialysis clinics are now open to provide treatment to dialysis patients. For the state of Texas, 57 of the 62 clinics that closed in anticipation of Ike’s landfall have reopened.
(more…)
Tags: Anticipation, Dialysis Facilities, Dialysis Patients, Electricity, Fresenius Dialysis Clinics, Fresenius Medical Care, Fresenius Medical Care North, Fresenius Medical Care North America, Houston Area, Hurricane, Landfall, People, State Of Texas
17 Sep 08 Therapy curbs insomnia in dialysis patients (Reuters)
Reuters - A type of psychotherapy called
cognitive-behavior therapy, or CBT, seems to reduce insomnia
and fatigue and improve the overall quality of sleep in
patients undergoing dialysis treatment, a study shows. CBT can
be an effective non-drug therapy for dialysis patients with
sleep problems, the investigators say.
(more…)
Tags: Cbt, Cognitive Behavior Therapy, Cognitive Therapy, Curbs, Dialysis Patients, Dialysis Treatment, Fatigue, Insomnia, Investigators, Psychotherapy, Reuters, Sleep, Sleep Problems
